Acceptability of probiotics, fecal microbiota transplantation, and emerging microbiome-derived therapies in patients with inflammatory bowel diseases: A cross-sectional Survey Study
Abstract
Background Microbiome-derived therapies (MDT), including probiotics and fecal microbiota transplantation (FMT), represent promising therapeutic approaches in inflammatory bowel disease (IBD). Objectives We aimed to evaluate patient preferences and determinants of MDT acceptability in IBD. Design Single-center cross-sectional survey conducted between April and July 2024. Methods Adult patients with IBD completed a structured questionnaire evaluating preferences regarding probiotics, FMT, and modified bacteria (chemically and genetically modified bacteria). Multivariate logistic regression identified factors associated with MDT acceptance. Results A total of 324 patients were included (205 Crohn’s disease, 63.3%; median disease duration 15.6 years; 82.4% in remission). Overall, 83.3% of patients accepted at least one MDT, whereas 16.7% rejected all treatments. When choosing between probiotics and FMT, 39.5% preferred probiotics, 37.7% were open to both, 14.2% rejected both, and 4.0% preferred FMT. Across all options, probiotics were the most acceptable (35.5%), followed by chemically modified bacteria (24.1%), while FMT was less frequently chosen (12.7%). Probiotic preference was mainly driven by practicality (21.1%) and perceived efficacy (21.9%). Higher educational level independently predicted MDT acceptance (aOR 1.26 per additional year; 95% CI 1.10–1.45; p<0.001), and moderate-to-severe disease activity predicted acceptance of probiotics and modified bacteria (aOR 2.25; 95% CI 1.09–5.14; p=0.03). Conclusion MDT acceptability was high in patients with IBD. Probiotics and modified bacteria were the most acceptable options, whereas FMT remained limited by patient reluctance. Educational level and disease activity were significantly associated with acceptance, underscoring the need to improve patient education on MDT and to integrate patient perspectives early in therapeutic development to ensure the design of acceptable MDT strategies.
Related
- Microbiome science in fecal microbiota transplantation for inflammatory bowel disease: a WoSCC-centered, three-database bibliometric and knowledge-mapping analysis, 2000–2025
- Current status of research on fecal microbiota transplantation in the postoperative management of inflammatory bowel disease
- Integrated effects of diet and probiotics on rumen microbiota and host physiology in ruminants.
- The microbiome bottleneck in seahorse aquaculture: a conceptual framework linking biofilm ecology, probiotics and larval survival
- From Microbiome Associations to Deployable Precision Probiotics in Animals: A Critical Narrative Review and Proposed Causal Evidence Framework for Next-Generation Probiotic Development
BibTeX
@article{grellier2026acceptability,
title = {{Acceptability of probiotics, fecal microbiota transplantation, and emerging microbiome-derived therapies in patients with inflammatory bowel diseases: A cross-sectional Survey Study}},
author = {Nathan Grellier and Clotilde Policar and Safa Hachicha and Samira Denguir and Anne Bourrier and Cecilia Landman and Isabelle Nion-Larmurier and Paul Mclellan and Julien Kirchgesner and Harry Sokol and Nicolas Delsuc and Enguerran Macia and Philippe Seksik},
journal = {Therapeutic Advances in Gastroenterology},
year = {2026},
month = oct,
doi = {10.1177/17562848261493689},
url = {https://hal.science/hal-05782141v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Acceptability of probiotics, fecal microbiota transplantation, and emerging microbiome-derived therapies in patients with inflammatory bowel diseases: A cross-sectional Survey Study
AU - Nathan Grellier
AU - Clotilde Policar
AU - Safa Hachicha
AU - Samira Denguir
AU - Anne Bourrier
AU - Cecilia Landman
AU - Isabelle Nion-Larmurier
AU - Paul Mclellan
AU - Julien Kirchgesner
AU - Harry Sokol
AU - Nicolas Delsuc
AU - Enguerran Macia
AU - Philippe Seksik
PY - 2026
DA - 2026/10/01
JO - Therapeutic Advances in Gastroenterology
DO - 10.1177/17562848261493689
UR - https://hal.science/hal-05782141v1
AB - Background Microbiome-derived therapies (MDT), including probiotics and fecal microbiota transplantation (FMT), represent promising therapeutic approaches in inflammatory bowel disease (IBD). Objectives We aimed to evaluate patient preferences and determinants of MDT acceptability in IBD. Design Single-center cross-sectional survey conducted between April and July 2024. Methods Adult patients with IBD completed a structured questionnaire evaluating preferences regarding probiotics, FMT, and modified bacteria (chemically and genetically modified bacteria). Multivariate logistic regression identified factors associated with MDT acceptance. Results A total of 324 patients were included (205 Crohn’s disease, 63.3%; median disease duration 15.6 years; 82.4% in remission). Overall, 83.3% of patients accepted at least one MDT, whereas 16.7% rejected all treatments. When choosing between probiotics and FMT, 39.5% preferred probiotics, 37.7% were open to both, 14.2% rejected both, and 4.0% preferred FMT. Across all options, probiotics were the most acceptable (35.5%), followed by chemically modified bacteria (24.1%), while FMT was less frequently chosen (12.7%). Probiotic preference was mainly driven by practicality (21.1%) and perceived efficacy (21.9%). Higher educational level independently predicted MDT acceptance (aOR 1.26 per additional year; 95% CI 1.10–1.45; p<0.001), and moderate-to-severe disease activity predicted acceptance of probiotics and modified bacteria (aOR 2.25; 95% CI 1.09–5.14; p=0.03). Conclusion MDT acceptability was high in patients with IBD. Probiotics and modified bacteria were the most acceptable options, whereas FMT remained limited by patient reluctance. Educational level and disease activity were significantly associated with acceptance, underscoring the need to improve patient education on MDT and to integrate patient perspectives early in therapeutic development to ensure the design of acceptable MDT strategies.
SN - 1756-283X
SN - 1756-2848
ER -